Loading organizations...
§ Private Profile · Carmiel, HaZafon, Israel
Clinical-stage biopharmaceutical company developing targeted cancer therapeutics for hematological malignancies, focused on AML and MDS.
BioSight is a clinical-stage biopharmaceutical company based in Airport City, Israel, that develops targeted therapeutics and pro-drugs for hematological malignancies like acute myeloid leukemia. The pre-revenue enterprise focuses on its lead candidate, aspacytarabine, which utilizes a targeted delivery mechanism to destroy leukemia cells while sparing healthy tissue in medically compromised patients. Operating with an estimated workforce of under 50 employees, the organization manages four clinical trials to advance its oncology pipeline. BioSight has raised over $65 million in total funding, including a $46 million Series C round backed by investors such as Arkin Bio Ventures, Primera Capital, and the Israel Biotech Fund. The company previously pursued a definitive merger agreement with Advaxis in 2021 before mutually terminating the transaction due to broader market conditions. BioSight was founded in 2000 by Dr. Stella Gengrinovitch and Mark Gengrinovitch.
BioSight has raised $40.0M across 2 funding rounds.
BioSight has raised $40.0M in total across 2 funding rounds.
BioSight has raised $40.0M across 2 funding rounds. Most recently, it raised $27.0M Series C Extension in December 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 2, 2020 | $27M Series C Plus | David Sidransky | Arkin BIO Ventures, Biotel, Migdal Insurance, Primera Capital, The Phoenix Insurance Company | Announced |
| May 16, 2016 | $13M Venture Round | Arkin Holdings, Primera Capital | Michael Ilan Management & Investments | Announced |
BioSight has raised $40.0M in total across 2 funding rounds.
BioSight's investors include David Sidransky, Arkin Bio Ventures, Biotel, Migdal Insurance, Primera Capital, The Phoenix Insurance Company, Arkin Holdings, Michael Ilan Management & Investments.